iShares 7-10 Year Treasury Bond ETF vs Oscar Health Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.37 (market cap $41.13B), while Oscar Health Inc trades at $33.29 (market cap $10.22B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 4× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Oscar Health Inc for 15 Days on average.
| IEF | OSCR | |
|---|---|---|
Market Cap | $41.13B | $10.22B |
Volume | 10,340,382 | 4,123,394 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $33.81 |
52-Week Low | $88.92 | $10.85 |
Typical Hold Time | 108 Days | 15 Days |
Enterprise Value | — | $6.57B |
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.295 with a modest 0.21% daily gain amid a challenging bond market environment. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent Treasury yield volatility and bond market selloffs have created headwinds for fixed income ETFs, while dividend distributions continue with recent payouts around $0.31-0.33 per share.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. While current yields provide income appeal, further rate increases could depress prices. Investors face the trade-off between defensive positioning and potential capital depreciation if the bond rout continues.
OSCR trades at $33.05, up 0.43% today, with strong technical momentum indicated by bullish moving averages. The company shows impressive growth with Q1 and Q2 2026 EPS beats and projected 2026 revenue of $15.3B. Valuation metrics appear reasonable with P/S of 0.63 and EV/EBITDA of 7.79, while profitability metrics show significant improvement from 2025 losses to projected 2026 net income of $551M.
The outlook remains positive with analyst consensus at $34.00 target and Strong Buy ratings from Zacks. Key opportunities include ACA market share gains and margin expansion, while risks center on rising medical costs and execution of growth targets. The stock faces near-term resistance at $34 with RSI suggesting potential overbought conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →